Recently, the 36th Annual Scientific Meeting of the Malaysian Oncological Society (ASCOMOS 2025) was grandly held in Johor Bahru, Malaysia. The conference gathered oncology experts from around the world to discuss the latest advances in cancer treatment. Guangzhou Fuda Cancer Hospital, as the only representative from China, demonstrated to the international community the “power of China” in the field of minimally invasive oncology.
△ President Niu Lizhi (second from right) with participating experts
Hospital President Prof. Niu Lizhi and Dr. Liu Shupeng, Director of Medical Department V, were invited to attend. The Fuda team not only received a special invitation to deliver a keynote report, but also had two academic papers selected for poster presentation: “NanoKnife Treatment for Unresectable Cholangiocarcinoma” and “Cryoablation of Pulmonary Ground-Glass Nodules.” This “double success” highlighted the hospital’s strong technical expertise and leading position in precision minimally invasive cancer treatment.
△ Poster presentation area
Hilar cholangiocarcinoma, due to its complex anatomy, surgical difficulty, and poor prognosis, has long been a major challenge in surgery. At the conference, Prof. Niu Lizhi gave a detailed introduction to the principles and advantages of NanoKnife (irreversible electroporation) ablation. This technology delivers high-voltage microsecond pulses that create irreversible nanopores in cell membranes, precisely inducing tumor cell apoptosis to achieve therapeutic goals. Compared with traditional surgical approaches, the NanoKnife can destroy tumor cells while sparing surrounding major blood vessels, bile ducts, and nerves—achieving both safety and effectiveness.
△ President Niu Lizhi delivering a keynote report
In his report, Prof. Niu further shared Fuda’s successful experience in combining NanoKnife ablation with chemotherapy. This integrative treatment model not only leverages the ablative effect of the NanoKnife but also enhances outcomes through electrochemical and electroimmunological effects. For diseases like hilar cholangiocarcinoma, where radical ablation is often difficult, this approach has demonstrated a synergistic “1+1>2” effect, significantly improving local control rates while showing promising results in both local tumor progression (LTP) and overall survival (OS). This innovative model provides an effective “China solution” for complex cases worldwide.
△ Prof. Niu Lizhi presenting a NanoKnife case
This successful appearance at a top international academic conference marks another milestone in Guangzhou Fuda Cancer Hospital’s commitment to “academic internationalization.” Prof. Niu remarked:
“Our core purpose in attending is not only to showcase technology, but also to build trust and foster exchange. Only by earning genuine recognition from the global medical community can we establish a foundation of trust for patients choosing China. Only by letting the world know that, in the struggle against cancer, China is offering new hope at the forefront, can our mission of ‘seeking the welfare of patients’ truly transcend borders.”
△ Prof. Niu Lizhi, Dr. Liu Shupeng (first from left), and Ms. Mo Caihong (first from right), Head of the Malaysia Service Center
After the conference, Dr. Liu Shupeng and his team visited Malaysia’s Mawar Medical Center and Curie Oncology. The delegation focused on key topics such as medical equipment, discipline development, clinical technologies, and patient services. They also held in-depth discussions on the latest advances in diagnosis and treatment, and expressed hopes of establishing a referral system in the future to allow more Malaysian cancer patients access to high-quality care.
This visit not only deepened the Fuda team’s understanding of healthcare needs in Southeast Asia, but also laid a solid foundation for future collaboration between China and Malaysia in oncology. With humility and determination, Guangzhou Fuda Cancer Hospital continues to advance its strategy of “bringing in” and “going out,” turning academic internationalization into real medical benefits for patients worldwide.
△ Dr. Ong Chiew Ping, President of Mawar Medical Center (second from right), personally hosted the visit
△ Prof. Ho Gwo Fuang, renowned Malaysian oncologist and attending physician at Curie Oncology (center), welcomed and accompanied the delegation